Affimed NV AFMD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 10:08 AM EDT
5.28quote price arrow down-0.02 (-0.38%)
Volume
22,676
52 week range
2.23 - 11.10
Loading...
  • Open5.42
  • Day High5.42
  • Day Low5.10
  • Prev Close5.30
  • 52 Week High11.10
  • 52 Week High Date05/22/23
  • 52 Week Low2.23
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap80.401M
  • Shares Out15.23M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta2.09
  • YTD % Change-16.32

KEY STATS

  • Open5.42
  • Day High5.42
  • Day Low5.10
  • Prev Close5.30
  • 52 Week High11.10
  • 52 Week High Date05/22/23
  • 52 Week Low2.23
  • 52 Week Low Date10/27/23
  • Market Cap80.401M
  • Shares Out15.23M
  • 10 Day Average Volume0.07M
  • Dividend-
  • Dividend Yield-
  • Beta2.09
  • YTD % Change-16.32

RATIOS/PROFITABILITY

  • EPS (TTM)-7.83
  • P/E (TTM)-0.67
  • Fwd P/E (NTM)-0.97
  • EBITDA (TTM)-112.518M
  • ROE (TTM)-100.55%
  • Revenue (TTM)8.875M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,280.22%
  • Debt To Equity (MRQ)33.48%

EVENTS

  • Earnings Date05/21/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Affimed NV

 

Profile

MORE
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a...
Andreas Harstrick M.D.
Chief Executive Officer, Chief Medical Officer, Member of the Management Board
Wolfgang Fischer Ph.D.
Chief Operating Officer, Member of the Management Board
Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Address
Gottlieb-Daimler-Strasse 2
Mannheim
68165
Germany